What was Cipla's consolidated net profit for the quarter ended June 30, and how did it compare to analyst expectations?

Cipla's consolidated net profit fell to 7.89 billion rupees ($81.73 million) for the quarter ended June 30, missing analysts' average estimate of 8.17 billion rupees, according to data compiled by LSEG.

What were the main reasons cited for Cipla's third consecutive quarterly profit decline in Q1?

The profit decline was driven by muted sales of generic cancer drugs and supply disruptions affecting lanreotide—a treatment for rare tumors—which weighed on its U.S. business.

Indian drugmaker Cipla's Q1 profit misses estimates

Jul 22, 2026

Cipla's Q1 profit fell 39.2% to 7.89 billion rupees, missing estimates due to muted generic cancer drug sales and supply disruptions affecting lanreotide in its U.S. business.

reuters

2026-07-22

Indian drugmaker Cipla's Q1 profit misses estimates

2026-10-27

India's Cipla misses quarterly profit view on muted US sales

Indian drugmaker Cipla's Q1 profit misses estimates

FAQ